Author

admin

Browsing

Former Navy SEAL and current GOP House lawmaker Rep. Eli Crane of Arizona delivered a pointed message to former President Barack Obama.

‘You’ve done enough damage. Probably best to sit this one out,’ the congressman told Obama in a post on X.

Crane made the comments in response to a post in which Obama declared, ‘Since we passed the Affordable Care Act, Republicans have tried over and over to repeal it. And over and over, they’ve failed — in part because millions of people now depend on the ACA for quality, affordable health care. Now Republicans are trying something different: quietly weakening the law and hoping you won’t notice. We can’t let them.’

GOP Sen. Mike Lee of Utah wrote in response to the Democrat’s post, ‘Obamacare was a great deal—for huge healthcare companies But it’s made healthcare less affordable for hardworking American families, who have seen their healthcare costs skyrocket—while a small handful of healthcare giants have reaped a windfall of billions of dollars a year.’

‘The worst part of Obamacare was putting able-bodied, working-age adults on government assistance instead of helping them find employment. I’ve been vocally against this since day one. Medicaid should be for needy children, families, and seniors. Not for those who can work!’ former Wisconsin Gov. Scott Walker, who is now the president of the Young America’s Foundation, wrote.

Fox News Digital reached out to the White House for comment on Obama’s post.

Obama served two consecutive terms as president, with his White House tenure spanning from early 2009 through early 2017, when he was succeeded by President Donald Trump.

This post appeared first on FOX NEWS

The ranking member of the House Judiciary Committee penned a letter to the Department of Justice demanding information about Ghislaine Maxwell’s recent prison transfer and meeting with a top Trump administration official. 

Rep. Jamie Raskin, D-Md., said the recent transfer of Maxwell – a convicted sex trafficker and Jeffrey Epstein’s former girlfriend and alleged accomplice – out of a maximum security prison in Tallahassee, Florida, gives ‘the strong appearance’ that the Trump administration ‘is attempting to cover up the full extent of the relationship between President Trump and Mr. Epstein.’ 

In the letter to Attorney General Pam Bondi and Bureau of Prisons Director William K. Marshall III, Raskin said Maxwell’s new home at a minimum-security federal prison camp in Bryan, Texas, provides ‘greater freedom for inmates.’ He argued that such an ‘extraordinary transfer’ would typically be ‘categorically off limits to sex offenders.’ 

‘These actions raise substantial concerns that the administration may now be attempting to tamper with a crucial witness, conceal President Trump’s relationship with convicted sex offenders, and coax Ms. Maxwell into providing false or misleading testimony in order to protect the President,’ Raskin wrote, according to a copy of the letter obtained by Fox News Digital. ‘The transfer also appears to violate both DOJ and Bureau of Prisons (BOP) policies.’ 

The letter asked for a cache of documents related to why Maxwell was transferred from Federal Correctional Institution (FCI) Tallahassee to Federal Prison Campe (FPC) Bryan. 

Raskin is also seeking a transcript and recording of Maxwell’s recent, hours-long meeting with Deputy Attorney General Todd Blanche at the Tallahassee prison. 

‘These meetings were highly unusual for several reasons. Mr. Blanche, who until ten months ago served as Donald Trump’s personal criminal defense lawyer, met with Ms. Maxwell and her attorney with no line prosecutors present. The meeting took place just days after DOJ leadership fired one of the chief career prosecutors on the Epstein matter,’ Raskin wrote, referencing the Justice Department’s firing of Maurene Comey from the Southern District of New York. 

Comey – the daughter of former FBI Director James Comey – most recently worked on the prosecution of Sean ‘Diddy’ Combs. Her other high-profile cases include the Epstein and Maxwell prosecutions. 

The DOJ confirmed criminal investigations into her father – as well as former CIA Director John Brennan last month. 

Reached by Fox News Digital on Wednesday, a Justice Department spokesperson confirmed the receipt of Raskin’s letter but declined to comment further.

In his letter to Bondi and Marshall, Raskin further argued that convicted sex offenders would typically be barred from federal prison camps, which provide ‘access to the community,’ and any transfer would require ‘multiple levels of review that would ordinarily take months to complete.’ He said any approval of a transfer ‘typically requires new facts or evidence’ and even so, ‘an inmate would then have to join a months-long waitlist for an opening at a camp.’

‘Ms. Maxwell, however, appears to have short-circuited the entire review process and jumped the queue, receiving a place in Federal Prison Camp (FPC) Bryan within a matter of days,’ Raskin wrote. ‘Neither DOJ nor BOP has provided anything like a satisfactory explanation for providing Ms. Maxwell this uniquely favorable treatment.’ 

The letter – also signed by all Democrats on the House Judiciary Committee – seeks a list of any administration officials who ‘were aware of, were involved in, or approved’ of the transfer. Raskin also demanded information regarding ‘any possible benefits to Ms. Maxwell, including transfers, changes to conditions of confinement, pardons, commutation, or changes to DOJ positions in ongoing matters.’

Raskin acknowledged that Maxwell was recently subpoenaed by the House Oversight Committee to testify. To Bondi and Marshall, the congressman said ‘there can be no question that your actions have served to send a clear message to Ms. Maxwell in the lead up to any testimony before Congress and the American public: this Administration can punish or reward her as it sees fit for its own purposes.’

This post appeared first on FOX NEWS

Vice President JD Vance is poised to meet with U.S. troops at a military installation in England Wednesday – capping off a high-stakes trip to the U.K. meeting with European leaders to discuss the war in Ukraine ahead of President Donald Trump’s Friday meeting with Russian President Vladimir Putin.

Vance’s visit to the U.K. comes as he’s sought to lay some groundwork with European allies leading up to Trump’s talk with Putin in Anchorage, Alaska – and as he’s turned up the heat on them to take greater ownership in the discussions since the conflict is in their backyard. 

The vice president is slated to visit Royal Air Force Base Fairford, where the U.S. Air Force’s 501st Combat Support Wing and the 99th Expeditionary Reconnaissance Squadron are based. Vance, a former Marine, is expected to voice appreciation for their service, according to a source familiar with Vance’s prepared remarks. 

The military installation serves as a key location for U.S. Air Force operations and is Air Force Global Strike Command’s preferred bomber forward operating base in Europe. U.S. Air Force bombers are regularly deployed to the military base as part of Bomber Task Force Europe 25-2 to integrate with NATO allies and sharpen the service’s global strike capabilities. 

Days after Putin invaded Ukraine in 2022, several Air Force B-52H Stratofortress bombers from Fairford conducted joint operations with Germany and Romania over NATO’s eastern flank.

There are approximately 10,000 U.S. troops stationed in the U.K., according to foreign policy think tank Council on Foreign Relations. 

Prior to addressing U.S. troops, Vance is poised to participate in calls with European leaders to discuss the conflict between Russia and Ukraine, Fox News Digital has learned. 

The calls come on the heels of multiple other discussions with European allies on a series of topics – including the war – during Vance’s U.K. visit. Vance has met with multiple U.K. leaders, including U.K. Foreign Secretary David Lammy. 

A U.S. official told Fox News Digital that Vance and Lammy discussed the relationship between the U.S. and the U.K. and the two allies’ shared economic and technology goals during a meeting on Friday at Lammy’s official residence, Chevening House, in Kent, England. 

Meanwhile, the two leaders also discussed the state of affairs in the Middle East, as well as negotiations between Russia and Ukraine, the U.S. official said. 

The two also met with representatives of Ukraine and other European allies at Chevening House on Saturday. The meeting led to ‘significant progress’ on ending the conflict in Ukraine, according to a U.S. official. 

No other details were provided regarding the Ukraine talks. It’s unclear if Vance will accompany Trump to Alaska for talks with Putin. 

However, Vance said in an interview with Fox News that he communicated to European leaders that the U.S. is ‘done with the funding of the Ukraine war business,’ and that European allies must assume more responsibility in ending the conflict. 

‘What we said to Europeans is simply, first of all, this is in your neck of the woods, this is in your back door, you guys have got to step up and take a bigger role in this thing, and if you care so much about this conflict you should be willing to play a more direct and a more substantial way in funding this war yourself,’ Vance told Fox News on Sunday. 

Congress has passed multiple measures to support Ukraine, totaling at least $175 billion in spending to aid Ukraine since February 2022, according to the Council on Foreign Relations. 

Meanwhile, Trump told reporters Monday that he’d know within minutes is Putin actually interested in a deal or not. Still, he said Moscow and Kyiv must come to terms with some ‘land swapping’ issues to sign off on a deal. 

‘If it’s a fair deal, I will reveal it to the European Union leaders and the NATO leaders and also to President Zelenskyy,’ Trump said. ‘I may say, ‘lots of luck, keep fighting,’ or I may say we can make a deal.’

Trump’s meeting with Putin also comes as his relationship with the Russian leader has soured as peace negotiations have lagged. While the two seemed to remain cordial with each other publicly during Trump’s first administration, that’s changed in recent weeks as Trump has grown fed up with Putin’s tactics. 

‘We get a lot of bulls— thrown at us by Putin, if you want to know the truth,’ Trump said during a Cabinet meeting on July 8. ‘He’s very nice all the time, but it turns out to be meaningless.’

This post appeared first on FOX NEWS

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Big pharma ETFs

Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on August 11, 2025.

1. iShares US Pharmaceuticals ETF (ARCA:IHE)

Total assets under management: US$539.44 million

Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

Of its holdings, Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are by far the largest portions in its portfolio, coming in at weightings of 25.51 percent and 17.68 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 5.04 percent, Viatris (NASDAQ:VTRS) at 4.94 percent and Merck & Co (NYSE:MRK) at 4.59 percent.

2. VanEck Pharmaceutical ETF (NASDAQ:PPH)

Total assets under management: US$494.34 million

Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

The ETF has 25 holdings, with the top five being Eli Lilly at a weight of 15.81percent, Johnson & Johnson at 12.08 percent, Novartis (NYSE:NVS) at 7.80 percent, Merck & Co. at 6.33 percent and Novo Nordisk (NYSE:NVO) at 5.94 percent.

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

Total assets under management: US$240.1 million

The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Johnson & Johnson with a weight of 5.25 percent, Gilead Sciences (NASDAQ:GILD) at 5.08 percent, AbbVie (NYSE:ABBV) at 4.95 percent, and both Pfizer (NYSE:PFE) and Merck & Co. at 4.83 percent each.

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

Total assets under management: US$150.91 million

The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Elanco Animal Health (NYSE:ELAN) with a weight of 4.21 percent, Tarsus Pharmaceuticals (NASDAQ:TARS) with a weight of 4.18 percent, Johnson & Johnson at 4.02 percent, Royalty Pharma at 3.98 percent and Viatris at 3.89 percent.

5. KraneShares MSCI All China Health Care Index ETF

Total assets under management: US$111.67 million

The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

The ETF tracks 46 holdings, and its top five are BeOne Medicines at 8.26 percent, Jiangsu Hengrui Medicine (SHA:600276) at 8.24 percent, WuXi Biologics (HKEX:2269) at 6.71 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 5.95 percent and CSPC Pharmaceutical Group (HKEX:1093) at 5.39 percent.

Securities Disclosure: I, Meagen Seatter, hold no investment interest in any of the companies mentioned in this article.

This post appeared first on investingnews.com

Keith Weiner, founder and CEO of Monetary Metals, discusses gold and silver’s performance so far this year and shares his outlook for the rest of 2025.

He also explains what makes today’s gold bull market different than those seen in prior years.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,530.69 as of August 5, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.04 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on August 5, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Tiziana Life Sciences (NASDAQ:TLSA)

Year-to-date gain: 227.8 percent
Market cap: US$256.36 million
Share price: US$2.26

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous delivery. Tiziana’s lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

Tiziana Life Sciences shares hit US$1.69 on March 7 after the company filed its investigational new drug application to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association. However, by early April that value had fallen back to US$0.78 per share.

A series of positive news flow later in the spring helped to give Tiziana shares another boost. In April, John Hopkins University and the University of Massachusetts commenced dosing of the biotech company’s intranasal foralumab in Phase 2 trials for patients with non-active secondary progressive multiple sclerosis. On May 7, the company shared positive results from the use of its lead candidate in improving the quality of life for patients with that form of multiple sclerosis.

Tiziana is also studying the use of intranasal foralumab for treating moderate Alzheimer’s disease. On May 9, it announced that PET scans of a patient with moderate Alzheimer’s showed a significant reduction in microglia activation associated with neuroinflammation after three months of treatment.

Shares of Tiziana reached US$1.62 on May 13.

On July 21, the company announced an ‘unexpected discovery’ in its findings of an immunologic analysis of the patient with Alzheimer’s disease.

‘In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques,’ the press release states. ‘This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.’

Tiziana’s share price climbed through the remainder of the month, hitting a year-to-date high of US$2.50 on July 31.

2. Palvella Therapeutics (NASDAQ:PVLA)

Year-to-date gain: 224.98 percent
Market cap: US$416.08 million
Share price: US$37.64

Palvella Therapeutics is a clinical-stage biopharma developing treatments targeting rare genetic skin diseases for which there are no FDA-approved therapies. The company’s product pipeline centers on its patented QTORIN platform, which has an initial focus on rare genetic skin diseases.

Its lead product candidate, QTORIN rapamycin, is currently in a Phase 2 clinical trial in cutaneous venous malformations, and a Phase 3 clinical trial in microcystic lymphatic malformations (LM). QTORIN rapamycin has been granted breakthrough therapy designation, orphan drug designation and fast track designation from the FDA for the treatment of microcystic LMs.

After starting the year at US$12.00, shares of Palvella had surged to US$20.99 by February 18. About a week earlier, the company had shared plans to expand the Phase 3 trial to include pediatric patients from three to five years of age. That momentum in Palvella’s share price continued to rally to US$29 per share on March 13.

June produced a number of significant milestones for Palvella. On June 9, the company received initial proceedings from a grant issued by the FDA Office of Orphan Products Development for its Phase 3 trial, and on June 23, it completed enrollment for the trial with 51 subjects, 25 percent over its target. The company closed out the month with news it was added to the broad-market Russell 3000 Index and the Russell 2000 Index.

The company said it remains on track to deliver top-line Phase 3 data in Q1 2026 to support its planned new drug application submission later that year.

While the company didn’t release news in July, Palvella Therapeutics’ share price climbed significantly through the month to hit a year-to-date high of US$39.87 on July 28.

3. OKYO Pharma (NASDAQ:OKYO)

Year-to-date gain: 163.03 percent
Market cap: US$117.35 million
Share price: US$3.13

OKYO Pharma is a clinical-stage biopharma developing therapies for the treatment of neuropathic corneal pain and dry eye disease. Its lead candidate is urcosimod, a non-steroidal anti-inflammatory and non-opioid analgesic.

So far in 2025, the company has achieved multiple milestones related to its Phase 2 trial of urcosimod for treatment of neuropathic corneal pain.

On April 30, OKYO announced plans to end the trial early to analyze the data from the patients who had completed the trial, with the goal of accelerating its clinical development and expanding the program. Supporting the decision was the fact that urcosimod had previously demonstrated safety in OKYO’s completed Phase 2 trial of the candidate to treat patients with dry eye disease.

The next day, news broke that the FDA granted urcosimod fast track designation for the treatment of neuropathic corneal pain. OKYO’s stock price reached US$1.57 on May 1.

On July 17, OKYO posted strong top-line data from its Phase 2 clinical trial, and stated it is planning a meeting with the FDA to discuss next steps for its lead drug candidate. The following day, OKYO received US$1.9 million in non-dilutive funding to support its clinical development of urcosimod.

Shares of OKYO hit a year-to-date high of US$3.17 on August 5.

4. IO Biotech (NASDAQ:IOBT)

Year-to-date gain: 129.47 percent
Market cap: US$144.28 million
Share price: US$2.16

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform, designed to activate T cells to target both tumor cells and the immune-suppressive cells. The company’s lead cancer vaccine candidate IO102-IO103, which has the brand name Cylembio, is currently in clinical trials.

The FDA granted breakthrough therapy designation to IO102-IO103 when used in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA for the treatment of advanced melanoma based on positive Phase 1/2 first line metastatic melanoma data.

At the start of the year, IO Biotech completed enrollment in its Phase 2 trial of IO102-IO103 with KEYTRUDA as a treatment given before and after surgery for resectable melanoma or head and neck cancer.

On February 4, the company published results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, which plays a key role in immune suppression.

In mid-March, IO Biotech was named to Fast Company’s list of the World’s Most Innovative Companies of 2025. The following month, the company presented new preclinical data for its lead candidate IO102-IO103 as well as IO170, which targets Transforming Growth Factor beta.

In its Q1 2025 financial results and business highlights released on May 14, IO Biotech shared that a readout of primary endpoint data from its pivotal Phase 3 trial of its lead investigational therapeutic cancer vaccine in patients with advanced melanoma is expected in the third quarter of 2025.

Shares of IO Biotech reached a year-to-date high of US$2.40 on July 28.

5. Spero Therapeutics (NASDAQ:SPRO)

Year-to-date gain: 110.95 percent
Market cap: US$124.12 million
Share price: US$2.22

Spero Therapeutics is developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need. The company’s lead drug candidate is tebipenem pivoxil hydrobromide (HBr), a late-stage development asset developed in collaboration with pharma giant GSK (NYSE:GSK) to treat complicated urinary tract infections (cUTIs), including pyelonephritis.

Spero has an exclusive license agreement with GSK for the development and commercialization of the drug candidate in all ex-Asia markets. The FDA has granted tebipenem HBr qualified infectious disease product and fast track designations.

Shares in Spero traded below US$1.00 for much of the first half of 2025. However, the stock’s value surged 245 percent on May 28 to reach US$2.35 per share after Spero reported that its Phase 3 trial evaluating tebipenem HBr for treating cUTIs met its primary endpoint and stopped early for efficacy. GSK plans to include the findings in a filing to the FDA during H2.

Spero shares reached a year-to-date high of US$3.04 on July 9.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

(TheNewswire)

TORONTO, ON, August 13, 2025 TheNewswire – Silver Crown Royalties Inc. ( Cboe: SCRI,OTC:SLCRF; OTCQX: SLCRF; FRA: QS0) ( ‘Silver Crown’ or the ‘Company’ ) is pleased to announce that, further to its press release dated August 7, 2025, it has closed the acquisition of a royalty on 90% of the cash equivalent of silver produced each quarter from the past producing Scotia Mine (the ‘Silver Royalty’ ) with EDM Resources Inc. ( TSX-V: EDM; FSE: P3Z) ( ‘EDM’ ). The Silver Royalty provides for minimum of the cash equivalent of 7,000 ounces per year for 10 years starting at commercial production on the Scotia Mine. SCRi paid $250,000 in cash at closing and issued 60,000 units (‘ Units ‘) to EDM per Unit at a deemed value of C$10.00, with each Unit consisting of a common share in the capital of SCRi (‘ Common Share ‘) and one warrant exercisable into an additional Common Share at a price of C$13.00 for a period of 36 months following the date hereof. SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty.

ABOUT EDM RESOURCES INC.

EDM Resources Inc. (‘EDM’) ( TSX-V: EDM; FSE: P3Z) is a Canadian exploration and mining company that has full ownership of the Scotia Mine and related facilities near Halifax, Nova Scotia. Through its wholly owned subsidiary, EDM also holds several prospective exploration licenses near its Scotia Mine and in the surrounding regions of Nova Scotia .

ABOUT Silver Crown Royalties INC.

Founded by seasoned industry professionals, Silver Crown Royalties ( Cboe: SCRI | OTCQX: SLCRF | FRA: QS0) is a publicly traded silver royalty company dedicated to generating free cash flow. Silver Crown (SCRi) currently holds five silver royalties. Its business model offers investors exposure to precious metals, providing a natural hedge against currency devaluation while mitigating the adverse effects of production-related cost inflation. SCRi strives to minimize the economic burden on mining projects while simultaneously maximizing shareholder returns. For further information, please contact:

Silver Crown Royalties Inc.

Peter Bures, Chairman and CEO

Telephone: (416) 481-1744

Email: pbures@silvercrownroyalties.com

FORWARD-LOOKING STATEMENTS

This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty . Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which SCRi will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; SCRi’s ability to enter into definitive agreements and close proposed royalty transactions; the inherent uncertainties related to the valuations ascribed by SCRi to its royalty interests; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects SCRi; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises on SCRi’s business, operations and financial condition, loss of key employees. SCRi has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SCRi undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities of the Company in Canada, the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in reliance upon exemptions from the prospectus and registration requirements under applicable securities laws, pursuant to a subscription agreement to be entered into by the Company and prospective investors. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

CBOE CANADA DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Copyright (c) 2025 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

Osisko Metals Incorporated (the ‘ Company or ‘ Osisko Metals ‘) ( TSX-V: OM ; OTCQX: OMZNF ; FRANKFURT: 0B51 ) is pleased to announce new drill results from the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec.

Osisko Metals Chief Executive Officer Robert Wares commented: ‘ Drill results at Gaspé Copper continue to exceed expectations. These new data expand the deposit further south and at depth with drill holes 30-1092 and 30-872, located respectively 230 metres and 440 metres south of the 2024 Mineral Resource Estimate (‘MRE’) model. Additional holes are planned in this resource expansion target area in the coming months over a surface of 450 metres by 550 metres, which we believe will add significant new tonnage to the MRE update, planned for Q1 2026.

New analytical results are presented below (see Table 1), including 20 mineralized intercepts from 7 new drill holes. Infill intercepts are located inside the 2024 MRE model ( see November 14, 2024 news release ), and are focused on upgrading inferred mineral resources to measured or indicated categories, as applicable. Expansion intercepts are located outside the 2024 MRE model and may potentially lead to additional resources that will be classified appropriately within the next MRE update. Some of the reported intercepts have contiguous shallower infill as well as deeper expansion (noted on Table 1 below as ‘Both**’). Maps showing hole locations are available at www.osiskometals.com .

Highlights:

  • Drill hole 30-1096
    • 730.7 metres averaging 0.29% Cu (infill and expansion)
  • Drill hole 30-1085
    • 219.0 metres averaging 0.41% Cu (infill)
    • 754.5 metres averaging 0.24% Cu (infill and expansion)
  • Drill hole 30-1092
    • 331.5 metres averaging 0.37% Cu (expansion)
  • Drill hole 30-1095
    • 309.5 metres averaging 0.26% Cu (infill)
  • Drill hole 30-1098
    • 115.0 metres averaging 0.29% Cu (infill)
    • 124.5 metres averaging 0.20% Cu (expansion)
  • Drill hole 30-1099
    • 614.7 metres averaging 0.23% Cu (infill and expansion)
  • Drill hole 30-0872
    • 92.1 metres averaging 0.24% Cu (expansion)
    • 47.2 metres averaging 1.14% Cu (expansion)

Table 1: Infill and Expansion Drilling Results

DDH No. From (m) To (m) Length (m) Cu % Ag g/t Mo % CuEq* Type**
30-0872 167.6 259.7 92.1 0.24 3.05 0.25 Expansion
And 342.0 389.2 47.2 1.14 11.84 1.22 Expansion
30-1085 3.0 222.0 219.0 0.41 2.79 0.44 Infill
And 355.5 1110 754.5 0.24 1.63 0.019 0.32 Both
(including) 355.5 763.3 407.8 0.21 1.49 0.020 0.30 Infill
(including) 763.3 1110.0 346.7 0.27 1.79 0.019 0.36 Expansion
30-1092 15.0 346.5 331.5 0.37 3.21 0.39 Expansion
30-1095 15.0 43.0 28.0 0.22 1.75 0.23 Infill
And 57.0 366.5 309.5 0.26 2.11 0.007 0.30 Infill
And 425.9 482.0 56.1 0.23 1.70 0.24 Expansion
And 524.7 550.5 21.9 0.42 2.04 0.43 Expansion
30-1096 27.0 78.0 51.0 0.21 1.40 0.22 Infill
And 129.0 177.0 48.0 0.17 1.20 0.18 Infill
And 331.5 1062.2 730.7 0.29 1.60 0.032 0.42 Both
(including) 331.5 727.5 396.0 0.21 1.45 0.032 0.34 Infill
(including) 727.5 1062.2 334.7 0.39 1.79 0.032 0.52 Expansion
30-1098 36.0 141.0 104.5 0.20 2.25 0.21 Infill
And 255.0 288.0 33.0 0.21 1.18 0.22 Infill
And 330.0 445.5 115.0 0.29 2.18 0.017 0.36 Infill
And 606.0 730.5 124.5 0.20 1.57 0.014 0.26 Expansion
And 753.0 813.0 60.0 0.35 2.88 0.006 0.39 Expansion
30-1099 31.5 66.0 34.5 0.22 1.08 0.23 Infill
And 105.3 720.0 614.7 0.23 1.59 0.016 0.30 Both
(including) 105.3 578.0 472.7 0.23 1.61 0.017 0.30 Infill
(including) 578.0 720.0 142.0 0.23 1.52 0.015 0.30 Expansion
And 862.2 1000.5 138.0 0.13 1.01 0.028 0.24 Expansion

* See explanatory notes below on copper equivalent values and Quality Assurance / Quality Control.
** ‘Both’ indicates drill holes that have contiguous shallower infill as well as deeper expansion intercepts.

Discussion

Drill hole 30-0872 was an old Noranda hole from the 1990s from which core was recovered and analyzed. The hole is located 440 metres south of the southern limit of 2024 MRE model and returned 92.1 metres averaging 0.24% Cu and 3.05 g/t Ag followed by a higher grade second intercept of 47.2 metres averaging 1.14% Cu and 11.8 g/t Ag (at the level of the C Zone skarn horizon), extending mineralization to a vertical depth of 390 metres. The first intercept starts at a depth of 168 metres and the overlying stratigraphy (Indian Cove hornfels) is unmineralized, but this waste material may be included as necessary strip in the next Whittle pit shell.

Drill hole 30-1085, located on top of Copper Mountain near the central part of the 2024 MRE model, intersected 219.0 metres averaging 0.41% Cu and 2.79 g/t Ag (infill), followed by a second intercept (starting 130 metres deeper) of 754.5 metres averaging 0.24% Cu, 1.63 g/t Ag and 0.019% Mo (both infill and expansion at depth).This hole extends mineralization near the centre of the deposit to a vertical depth of 1110 metres.

Drill hole 30-1092 is located 230 metres south of the southern limit of 2024 MRE model and returned 331.5 metres averaging 0.37% Cu and 3.21 g/t Ag (from surface down to the P4 stratigraphic level below the C Zone). This hole is located approximately 15 metres west of previously-reported hole 30-1067, which had failed to drill through a pillar of the B Zone.

Drill hole 30-1095, located in the south-central part of the 2024 MRE model, intersected 309.5 metres averaging 0.26% Cu and 2.11 g/t Ag (infill). This was followed by 56.1 metres averaging 0.23% Cu and 1.70 g/t Ag and then by another 21.9 metres averaging 0.42% Cu and 2.04 g/t Ag (both expansion), extending mineralization to a vertical depth of 550 metres.

Drill hole 30-1096, located in the central part of the 2024 MRE model, intersected two short (51 and 48 metre-long) mineralized zones, followed by 730.7 metres averaging 0.29% Cu, 1.60 g/t Ag, and 0.032% Mo (0.42% CuEq). The latter includes an expansion lower intercept, below the base of the 2024 MRE model, of 334.7 metres averaging 0.39% Cu, 1.79 g/t Ag, and 0.032% Mo (0.52% CuEq). This hole extends mineralization to a vertical depth of 1062 metres.

Drill hole 30-1098, located near the western margin of the 2024 MRE model, intersected 104.5 metres averaging 0.20% Cu and 2.25 g/t Ag (infill), followed by 115.0 metres averaging 0.29% Cu and 2.18 g/t Ag (infill). This was followed by 124.0 metres averaging 0.20% Cu and 1.57 g/t Ag and then by another 60.0 metres averaging 0.35% Cu and 2.88 g/t Ag (both expansion), extending mineralization to a vertical depth of 813 metres.

Drill hole 30-1099, located near the central part of the 2024 MRE model, adjacent to the Copper Mountain pit, intersected a short (34-metre-long) mineralized zone followed by 614.7 metres averaging 0.23% Cu, 1.59 g/t Ag, and 0.016% Mo (both infill and expansion), followed by a third intersection of 138 metres that averaged 0.13% Cu, 1.01 g/t Ag, and 0.028% Mo (expansion), extending mineralization in the porphyry core of the deposit to a vertical depth of 1000 metres.

Mineralization at Gaspé Copper is of porphyry copper/skarn type and occurs as disseminations and stockworks of chalcopyrite with pyrite or pyrrhotite and minor bornite and molybdenite. At least five retrograde vein/stockwork mineralizing events have been recognized at Copper Mountain, which overprint earlier prograde skarn and porcellanite-hosted mineralization throughout the Gaspé Copper system. Porcellanite is a historical mining term used to describe bleached, pale green to white potassic-altered hornfels. Subvertical stockwork mineralization dominates at Copper Mountain whereas prograde bedding-replacement mineralization, that is mostly stratigraphically controlled, dominates in the area of Needle Mountain, Needle East, and Copper Brook. High molybdenum grades (up to 0.5% Mo) were locally obtained in both the C Zone and E Zone skarns away from Copper Mountain.

The 2022 to 2024 Osisko Metals drill programs were focused on defining open-pit resources within the Copper Mountain stockwork mineralization ( see May 6, 2024 MRE press release ). Extending the resource model south of Copper Mountain into the poorly-drilled prograde skarn/porcellanite portion of the system subsequently led to a significantly increased resource, mostly in the Inferred category ( see November 14, 2024 MRE press release ).

The current drill program is designed to convert the November 2024 MRE to Measured and Indicated categories, as well as test the expansion of the system deeper into the stratigraphy and laterally to the south and southwest towards Needle East and Needle Mountain respectively. The November 2024 MRE was limited at depth to the base of the L1 skarn horizon (C Zone), and all mineralized intersections below this horizon represent potential depth extensions to the deposit, to be included in the next scheduled MRE update in Q1 2026.

All holes are being drilled sub-vertically into the altered calcareous stratigraphy which dips 20 to 25 degrees to the north. The L1 (C Zone) the L2 (E Zone) skarn/marble horizons were intersected in most holes, as well as intervening porcellanites that host the bulk of the disseminated copper mineralization.

Table 2: Drill hole locations

DDH No. Azimuth (°) Dip (°) Length (m) UTM E UTM N Elevation
30-0872 0.00 -90.00 594.3 316531.1 5425181.2 706.3
30-1085 0.00 -90.00 1110.0 316020.0 5426400.0 742.5
30-1092 0.00 -90.00 741.0 316342.0 5425425.0 609.0
30-1095 0.00 -90.00 696.0 316409.1 5425733.0 572.8
30-1096 0.00 -90.00 1069.0 316198.0 5426305.0 753.3
30-1098 0.00 -90.00 861.0 316034.0 5425948.0 600.5
30-1099 0.00 -90.00 1041.0 315700.0 5426462.0 603.7

Explanatory note regarding copper-equivalent grades

Copper Equivalent grades are expressed for purposes of simplicity and are calculated taking into account: 1) metal grades; 2) estimated long-term prices of metals: US$4.25/lb copper, $20.00/lb molybdenum and US$24/oz silver; 3) estimated recoveries of 92%, 70% and 70% for Cu, Mo and Ag respectively; and 4) net smelter return value of metals as percentage of the price, estimated at 86.5%, 90.7% and 75.0% for Cu, Mo and Ag respectively.

Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Mr. Bernard-Olivier Martel, P. Geo. (OGQ 492), an independent ‘qualified person’ as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (‘NI 43-101’).

Quality Assurance / Quality Control

Mineralized intervals reported herein are calculated using an average 0.12% CuEq lower cut-off over contiguous 20-metre intersections (shorter intervals as the case may be at the upper and lower limits of reported intervals). Intervals of 20 metres or less are not reported unless indicating significantly higher grades . True widths are estimated at 90 – 92% of the reported core length intervals.

Osisko Metals adheres to a strict QA/QC program for core handling, sampling, sample transportation and analyses, including insertion of blanks and standards in the sample stream. Drill core is drilled in HQ or NQ diameter and securely transported to its core processing facility on site, where it is logged, cut and sampled. Samples selected for assay are sealed and shipped to ALS Canada Ltd.’s preparation facility in Sudbury. Sample preparation details (code PREP-31DH) are available on the ALS Canada website. Pulps are analyzed at the ALS Canada Ltd. facility in North Vancouver, BC. All samples are analyzed by four acid digestion followed by both ICP-AES and ICP-MS for Cu, Mo and Ag.

Option Grant

The Company announces that, effective August 12, 2025, it has granted to an employee of the Company an aggregate of 125,000 stock options (‘Options’) pursuant to the Osisko Metals omnibus equity incentive plan.

The Options have an exercise price of $0.44 per share and a five-year term from the date of grant, and vest annually in equal thirds beginning on the first anniversary of the date of grant.

About Osisko Metals

Osisko Metals Incorporated is a Canadian exploration and development company creating value in the critical metals sector, with a focus on copper and zinc. The Company acquired a 100% interest in the past-producing Gaspé Copper mine from Glencore Canada Corporation in July 2023. The Gaspé Copper mine is located near Murdochville in Québec s Gaspé Peninsula. The Company is currently focused on resource expansion of the Gaspé Copper system, with current Indicated Mineral Resources of 824 Mt averaging 0.34% CuEq and Inferred Mineral Resources of 670 Mt averaging 0.38% CuEq (in compliance with NI 43-101). For more information, see Osisko Metals’ November 14, 2024 news release entitled ‘Osisko Metals Announces Significant Increase in Mineral Resource at Gaspé Copper’. Gaspé Copper hosts the largest undeveloped copper resource in eastern North America, strategically located near existing infrastructure in the mining-friendly province of Québec.

In addition to the Gaspé Copper project, the Company is working with Appian Capital Advisory LLP through the Pine Point Mining Limited joint venture to advance one of Canada s largest past-producing zinc mining camps, the Pine Point project, located in the Northwest Territories. The current mineral resource estimate for the Pine Point project consists of Indicated Mineral Resources of 49.5 Mt averaging 5.52% ZnEq and Inferred Mineral Resources of 8.3 Mt averaging 5.64% ZnEq (in compliance with NI 43-101). For more information, see Osisko Metals June 25, 2024 news release entitled ‘Osisko Metals releases Pine Point mineral resource estimate: 49.5 million tonnes of indicated resources at 5.52% ZnEq’. The Pine Point project is located on the south shore of Great Slave Lake, NWT, close to infrastructure, with paved road access, an electrical substation and 100 kilometers of viable haul roads.

For further information on this news release, visit www.osiskometals.com or contact:

Don Njegovan, President
Email: info@osiskometals.com
Phone: (416) 500-4129

Cautionary Statement on Forward-Looking Information

This news release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Any statement that involves predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always, using phrases such as ‘expects’, or ‘does not expect’, ‘is expected’, ‘interpreted’, ‘management’s view’, ‘anticipates’ or ‘does not anticipate’, ‘plans’, ‘budget’, ‘scheduled’, ‘forecasts’, ‘estimates’, ‘potential’, ‘feasibility’, ‘believes’ or ‘intends’ or variations of such words and phrases or stating that certain actions, events or results ‘may’ or ‘could’, ‘would’, ‘might’ or ‘will’ be taken, occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This news release contains forward-looking information pertaining to, among other things: the tax treatment of the FT Units; the timing of incurring the Qualifying Expenditures and the renunciation of the Qualifying Expenditures; the ability to advance Gaspé Copper to a construction decision (if at all); the ability to increase the Company’s trading liquidity and enhance its capital markets presence; the potential re-rating of the Company; the ability for the Company to unlock the full potential of its assets and achieve success; the ability for the Company to create value for its shareholders; the advancement of the Pine Point project; the anticipated resource expansion of the Gaspé Copper system and Gaspé Copper hosting the largest undeveloped copper resource in eastern North America.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, without limitation, assumptions about: the ability of exploration results, including drilling, to accurately predict mineralization; errors in geological modelling; insufficient data; equity and debt capital markets; future spot prices of copper and zinc; the timing and results of exploration and drilling programs; the accuracy of mineral resource estimates; production costs; political and regulatory stability; the receipt of governmental and third party approvals; licenses and permits being received on favourable terms; sustained labour stability; stability in financial and capital markets; availability of mining equipment and positive relations with local communities and groups. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information are set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.ca) under Osisko Metals’ issuer profile. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f12ebf89-5e37-4f45-86a2-3476365db1e2
https://www.globenewswire.com/NewsRoom/AttachmentNg/2a67e753-d0a2-4e74-8717-d7ee5bf555b7

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

Undrilled silver-rich and polymetallic occurrences are dispersed across a 55 km highly prospective east-west corridor

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) (‘Silver47’ or the ‘Company’) is pleased to provide a review of drill targeting across the highly-prospective Bonnifield District at the Red Mountain project near Fairbanks, Alaska (the ‘Red Mountain Project’).

Highlights:

  • Strong Alaskan High-Grade Resource Base: The Red Mountain Project already hosts an inferred mineral resource estimate of 15.6Mt at 336 g/t AgEq* totaling 168.6 million silver equivalent ounces comprised of two resource zones, Dry Creek and West Tundra Flats.
  • Leveraging Past Work: A database of historic geochemical and geophysical data, including 2,543 rock samples, 7,948 soil samples and 15,862 XRF soil samples has revealed a series of new targets outside the current resource zones that the Company is developing for drilling in 2026.
  • High Prospectivity and Unique Discovery Potential: Ongoing compilation highlights at least 35 mineralized prospects across the Red Mountain Project covering a 55 km trend many of which are undrilled or represent preliminary drilled discoveries open to expansion.
  • U.S. Silver and Critical Metal Focus: Multiple zones of high-grade surface mineralization marked by samples collected by a previous operator representing significant polymetallic upside are highlighted by grades of:
  • 1,295 g/t silver at the Galleon target
  • 3.8 g/t gold at the Horseshoe target
  • 16.2% copper at the Kiwi target
  • 32% zinc at the Anderson Mountain target
  • 20% lead at the Jack Frost target
  • 4,850 g/t antimony at the Bib target
  • 149 g/t gallium northeast of the West Tundra Flats Deposit
  • 98 g/t indium at the Jack Frost target
  • 0.13% tin at the Sheep Creek target
  • Drilling On-Going with Assays Pending: Nine holes have been completed at the Dry Creek and West Tundra Flats deposits where zones of massive, semi-massive and disseminated sulfides have been intersected in step-out and infill holes.

Galen McNamara, CEO, stated: ‘Our Red Mountain Project in Alaska is emerging as a premier silver and critical metals asset in the U.S. By leveraging extensive historic data, we’ve identified dozens of high-potential targets along broadly mineralized trends. The prospectivity of these targets was first identified by past operators, and I agree; the data suggest the likely presence of additional undiscovered and potentially giant VMS deposits on the project. I am unaware of any other domestic mineral projects with similar polymetallic discovery potential. In addition, ongoing drilling at Dry Creek and West Tundra Flats continues to intersect promising sulfide zones, with assays pending, positioning Red Mountain to deliver significant value and strengthen domestic critical mineral supply chains in the future.’

*Table 1: Combined Open Pit and Underground Inferred Mineral Resource Estimate for the Red Mountain Project, Alaska 

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10967/262306_8647920a74a5686f_002full.jpg

  1. The 2024 Red Mountain MRE was estimated and classified in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (‘CIM’) ‘Estimation of Mineral Resources and Mineral Reserves Best Practice Guidelines’ dated November 29, 2019, and the CIM ‘Definition Standards for Mineral Resources and Mineral Reserves’ dated May 10, 2014.
  2. Mr. Warren Black, M.Sc., P.Geo. of APEX Geoscience Ltd., a QP as defined by NI 43-101, is responsible for completing the 2024 Mineral Resource Estimate, effective January 12, 2024.
  3. Mineral resources that are not mineral reserves have not demonstrated economic viability. No mineral reserves have been calculated for Red Mountain. There is no guarantee that any part of the mineral resources discussed herein will be converted to a mineral reserve in the future.
  4. The estimate of mineral resources may be materially affected by environmental, permitting, legal, title, market, or other relevant factors.
  5. The quantity and grade of reported Inferred Resources is uncertain, and there has not been sufficient work to define the Inferred Mineral Resource as an Indicated or Measured Mineral Resource. It is reasonably expected that most of the Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration.
  6. All figures are rounded to reflect the relative accuracy of the estimates. Totals may not sum due to rounding. Reported grades are undiluted.
  7. A standard density of 2.94 g/cm³ is assumed for mineralized material and waste rock. Overburden density is set at 1.8 g/cm³. For mineralized material blocks with iron assays close enough to estimate an iron value for the block, density is calculated using the formula: density (g/cm³) = 0.0553 * Fe (%) + 2.5426.
  8. Metal prices are US$2,750/tonne Zn, US$2,100/tonne Pb, US$8,880/tonne Cu, US$1,850/oz Au, and US$23/oz Ag.

Figure 1. Plan Map of Red Mountain Project.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10967/262306_8647920a74a5686f_003full.jpg

Figure 2. Mineralized core from WT25-38 at the West Tundra Flat Deposit showing disseminated, semi-massive and massive sulfides consisting of pyrite, pyrrhotite, sphalerite, galena and chalcopyrite (172.65 to 180.5m downhole).

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10967/262306_8647920a74a5686f_004full.jpg

The Targets

Priority volcanogenic massive sulfide (VMS) exploration targets at the Red Mountain Project are dispersed across the highly prospective Bonnifield mining district. The targets vary from zinc-rich to copper-rich and many have associated high-grade silver and local gold mineralization.

Four main target trends are defined and include: Dry Creek Syncline, Keevy Trend, Last Chance Corridor and Wood River trend (Figure 1). Many of the targets across the Dry Creek Syncline area (Figure 1) were known historically, however, numerous high-priority targets across the Keevy and Last Chance areas were more recently identified through regional stream sediment, ridge-spur soil and rock geochemical surveys and project-wide EM geophysical surveys completed by a past project operator. Of the 30 known targets as well as other un-explored EM targets, only eleven targets have been drill tested, five of those with less than three holes each.

The Dry Creek Syncline: The best known targets associated with the Dry Creek Syncline are the Dry Creek and WTF deposits (combined inferred mineral resource of 15.6 million tonnes at 7% ZnEq or 335.7 g/t AgEq, totaling 168.6 million silver equivalent ounces*). Previous drilling at Dry Creek have returned high-grade intercepts, such as 22.3 m at 601 g/t AgEq (150.6 g/t Ag, 0.82 g/t Au, 5.86% Zn, 2.60% Pb, 0.13% Cu, DC24-105) from 18.9 m down hole.

VMS targets are located along both limbs of the project-scale, east-west trending Dry Creek syncline where approximately 40 km of prospective VMS stratigraphy (Mystic and Sheep Creek members of the Totatlanika schist) is well exposed (Figure 1). Many targets along the syncline are associated with pronounced EM anomalies and have been mostly defined by stream, soil and rock-chip geochemistry and limited ground geophysical surveys (magnetics and CSAMT). High priority targets across the Dry Creek Syncline area include:

  • Hunter Target: Massive sulfide mineralization at the Hunter target, 5.8 km west of Dry Creek, has been traced for over 500 m within a carbonaceous phyllite that is traced for over 1 km. Rock chip sampling of the discovery Hunter outcrop returned assays up to 616 g/t Ag, 18.6% Zn, 5.4% Pb, 2.5% Cu, and 0.33 g/t Au. Six drill holes in 2018, 2019 and 2021 successfully tested the dip-extent of the massive sulfide lens highlighted by 1.4m of 17.4% Zn, 3.9% Pb, 1.6% Cu, 90 g/t Ag and 0.23 g/t Au (HR18-01)2 and 1.8m of 13.8% Zn, 3.1% Pb, 56 g/t Ag, 0.2 g/t Au and 0.9% Cu (HR18-02)2. VMS-related mineralization at Hunter is therefore open in all directions and further drilling testing of the strike- and dip-extent is warranted.

  • Glacier Creek: The Glacier Creek suite of targets are approximately 12.3 km northwest of Dry Creek. The ~6 km long target area is primarily underlain by the highly-prospective Totatlanika schists and is defined by numerous EM anomalies and broad km-scale colour anomalies and associated sericite alteration. Rock-chip sampling is sparce and soil-surveys have only been ridge-spur, however, numerous multi-element geochemical anomalies have been defined together with barium enrichment in many samples. Seven holes were drilled across two programs covering a 2 km trend in 1998 and 2019. Additional geological mapping, soil and rock geochemical surveys are clearly warranted to advance the known targets and to define drill targets.

  • Galleon Target: The Galleon target is approximately 9.0 km north of Dry Creek. Similar to Glacier Creek, the Galleon target is primarily underlain by the Totatlanika schist where numerous showings of VMS-style, high-Pb-Zn-Cu massive sulfide mineralization have been discovered. Importantly, numerous samples from Galleon returned elevated to high-grade Ag and Au mineralization. Rock samples with up to 1,265 g/t Ag, 2.18 g/t Au, 2.4% Zn, 1.656% Pb and 1.7% Cu have been reported. Additional geological mapping, soil and rock geochemical surveys are clearly warranted to advance the known targets, followed by drill testing.

The Keevy Trend: The Keevy VMS trend consists of numerous high-grade VMS targets dispersed along 25 km of favorable Keevy Peak Formation and Healy Schist stratigraphy south of the Dry Creek Syncline area (Figure 1). From east to west the targets comprise Lowrider, Easy Ivan, Jack Frost, Yogi, Kiwi, and Yeti with multiple unexplored EM targets west of Yeti (Figure 1). These targets have massive sulfide occurrences comprised of sphalerite, galena and chalcopyrite with other key VMS indicators such as chert, black barite and broad zones of sericite alteration and strongly anomalous base-metal soil anomalies. Highlights and key indicators of VMS potential from the Keevy VMS trend include:

  • Kiwi: up to 316 g/t Ag, 16.2% Cu, 10.3% Zn, 1.7% Pb, and 2.8 g/t Au in rock samples

  • Easy Ivan: up to 87.1 g/t Ag, 6.0% Zn, 12.3% Pb, and 0.45% Cu in rock samples

  • Jack Frost: up to 285 g/t Ag, 14.0% Zn, 20.0% Pb, and 1.1% Cu in rock samples

  • Yeti: black barite with elevated silver and strong base metal soil anomalism

Besides sparce ridge-spur and local grid soil surveys, prospecting and rock sampling many of the targets are under-explored and represent priority targets for follow-up. Geological mapping and infill soil geochemical surveys are planned to advance many of the targets along the highly prospective Keevy Trend.

Last Chance Corridor: The Last Chance area of prospective VMS targets is centered approximately 40 km west of the Dry Creek deposit (Figure 1). These targets may represent the western extent of the Keevy Trend. Seven targets have been defined covering a prospective corridor of 15 km primarily underlain by the Healy Schist and include from east to west; Copper Creek, Grapple, Bib West, Bullseye, Ringer, Sheep Creek and Horseshoe. The VMS lenses exposed in outcrop consist of pyrrhotite, pyrite and/or sphalerite, galena and chalcopyrite. Only the Sheep Creek target has been drill tested (1979 program by US Borax1) and all targets are primarily defined based on rock, soil and stream sediment anomalism and airborne and local ground-based geophysical methods. Highlights from previous rock-chip sampling include:

  • Horseshoe: up to 8.3% Zn, 4.6% Pb, 0.76% Cu, 44 g/t Ag and 3.8 g/t Au in rock samples

  • Bib: up to 7.3% Zn, 5.1% Pb, 0.3% Cu, 60 g/t Ag and 0.47 g/t Au in rock samples

  • Grapple: up to 5.1% Zn, 13.2% Pb, 0.79% Cu and 139 g/t Ag in rock samples

  • Ringer: up to 0.72% Cu, 27 g/t Ag and 1.0 g/t Au in rocks samples

  • Sheep Creek: up to 306 g/t Ag, 4.3% Zn, 3.98% Pb, and 0.18% Cu in rock samples and 24.5 m of 1.3% Zn,1.0% Pb and 0.127% Sn in historical drilling1

Follow-up geological mapping, infill soil geochemical surveys and additional higher-resolution magnetic surveys are planned to further advance many of the Last Chance targets.

Wood River Trend: Four high-grade VMS targets cover a 24 km trend on the southern limb of a district-scale anticlinal fold that runs parallel to the Dry Creek syncline (Figure 1). The targets are hosted in prospective Healy and Wood River Assemblage schists which host VMS-related mineralization elsewhere in the Bonnifield district. From east to west the targets include West Fork, Cirque, Virginia Creek and Anderson Mountain. Select historical rock-chip sampling and select drilling highlights include:

  • West Fork: up to 3.5% Zn, 2.5% Pb, 1.2% Cu and 73g/t Ag in rock samples

  • Cirque: up to 487 g/t Ag, 13.2% Zn, 3.8% Pb, 12.4% Cu and 3.7 g/t Au in rock samples

  • Virginia Creek: historical drilling, 14.8m at 3.3% Zn, 0.8% Pb, 78 g/t Ag, 0.2g/t Au and 0.5% Cu1 and rock samples up to 2.8% Zn, 0.65% Pb, 74.1 g/t Ag, 1.01 g/t Au and 1.3% Cu

  • Anderson Mountain: historical drilling, 161 g/t Ag, 0.6 m at 22% Zn, 4.8% Pb and 0.6% Cu1 and up to 151 g/t Ag, 32% Zn, 8.8% Pb and 3.8% Cu in rock samples. The prospective VMS horizon is mapped for over 240 m

Follow-up geological mapping, infill soil geochemical surveys and additional higher-resolution magnetic surveys are warranted to further advance many of the Wood River trend of VMS targets.

Exploration Update

Drilling is ongoing at the Red Mountain Project where nine holes have been completed. Two holes have been completed at Dry Creek and seven holes at WTF. Zones of massive, semi-massive and disseminated sulfide mineralization have been intersected in both infill and step-out holes.

Data Verification

Historical data referenced herein, including but not limited to assay results, drill intercepts, and geological interpretations from previous exploration activities, have been sourced from publicly available records, archived reports, and third-party databases believed to be reliable. However, Silver47 has not independently verified this historical data through resampling, re-assaying, or other confirmatory methods due to the remote locations of the original samples or sites. As such, the Company cautions that this historical information may not conform to current NI 43-101 standards and should not be relied upon.

No new data verification procedures were undertaken specifically for this release beyond a review of available documentation. The Company plans to conduct future verification work, including drilling and sampling, to confirm and update these historical findings as part of ongoing exploration programs.

Qualified Person

The technical content of this news release has been reviewed and approved by Galen McNamara, P. Geo., the CEO of the Company and a qualified person as defined by National Instrument 43-101.

References

  1. Data reported by White Rock Minerals, WRM ASX announcement August 20th, 2018.

About Silver47 Exploration

Silver47 Exploration Corp. is a mineral exploration company, focused on uncovering and developing silver-rich deposits in North America. The Company is creating a leading high-grade US-focused silver developer with a combined resource totaling 236 Moz AgEq at 334 g/t AgEq inferred and 10 Moz at 333 g/t AgEq Indicated. With operations in Alaska, Nevada and New Mexico, Silver47 Exploration is anchored in America’s most prolific mining jurisdictions. For detailed information regarding the resource estimates, assumptions, and technical reports, please refer to the NI 43-101 Technical Report and other filings available on SEDAR at www.sedarplus.ca. The Company trades on the TSXV under the ticker symbol AGA and OTCQB under the ticker symbol AAGAF.

For more information about the Company, please visit www.silver47.ca and see the Technical Report filed on SEDAR+ (www.sedarplus.ca) and titled ‘Technical Report on the Red Mountain VMS Property Bonnifield Mining District, Alaska, USA with an effective date January 12, 2024, and prepared by APEX Geoscience Ltd.’

Follow us on social media for the latest updates:

    On Behalf of the Board of Directors,

    Mr. Galen McNamara
    CEO & Director

    For investor relations
    Giordy Belfiore
    604-288-8004
    gbelfiore@silver47.ca

    No securities regulatory authority has either approved or disapproved of the contents of this release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

    FORWARD-LOOKING STATEMENTS

    This release contains certain ‘forward-looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘expect’, ‘intend’, ‘estimate’, ‘upon’ ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. Forward-looking statements and information include, but are not limited to: the Company’s exploration and development activities and plans. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: the ability to close the Offering, including the time and sizing thereof, the insider participation in the Offering and receipt of required regulatory approvals; the use of proceeds not being as anticipated; the Company’s ability to implement its business strategies; risks associated with general economic conditions; adverse industry events; stakeholder engagement; marketing and transportation costs; loss of markets; volatility of commodity prices; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; industry and government regulation; changes in legislation, income tax and regulatory matters; competition; currency and interest rate fluctuations; and the additional risks identified in the Company’s financial statements and the accompanying management’s discussion and analysis and other public disclosures recently filed under its issuer profile on SEDAR+ and other reports and filings with the TSXV and applicable Canadian securities regulators. The forward-looking information are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws.

    No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262306

    News Provided by Newsfile via QuoteMedia

    This post appeared first on investingnews.com